Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report is about pharma and health.
Directly affected
- No company is named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | -1.60% | +0.57% | base | +0.23% | after close | after close | after close |
| XBI | +0.68% | +2.56% | base | -1.61% | after close | after close | after close |
| LLY | -5.27% | +0.16% | base | -0.24% | after close | after close | after close |
| JNJ | -2.55% | -0.98% | base | +0.74% | after close | after close | after close |
| PFE | +1.93% | +1.84% | base | -0.07% | after close | after close | after close |
| MRK | -0.13% | +0.71% | base | -0.58% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings BioSpace
Source: BioSpace
This story
| Company | When | Move | Status |
|---|---|---|---|
| JNJ | that day | +0.74% | still updating |
| JNJ | three days earlier | -0.98% | final price |
| JNJ | five days earlier | -2.55% | final price |
| LLY | that day | -0.24% | still updating |
| LLY | three days earlier | +0.16% | final price |
| LLY | five days earlier | -5.27% | final price |
| MRK | that day | -0.58% | still updating |
| MRK | three days earlier | +0.71% | final price |
| MRK | five days earlier | -0.13% | final price |
| PFE | that day | -0.07% | still updating |
| PFE | three days earlier | +1.84% | final price |
| PFE | five days earlier | +1.93% | final price |
| XBI | that day | -1.61% | still updating |
| XBI | three days earlier | +2.56% | final price |
| XBI | five days earlier | +0.68% | final price |
| XLV | that day | +0.23% | still updating |
| XLV | three days earlier | +0.57% | final price |
| XLV | five days earlier | -1.60% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 24 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 70 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 37 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 44 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 70 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 84 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 50 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 86 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
This story
12 out of 100Price not final
“Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings” scores 12 out of 100. The score uses 1 sources. The price is not final yet.